Patents Issued in January 30, 2024
  • Systems and methods of forming and analyzing dissolvable articles
    Patent number: 11884902
    Abstract: Systems and methods of forming and analyzing a dissolvable article are provided herein. In an embodiment, a method of analyzing a dissolvable article includes providing a dissolvable article comprising a water-soluble block copolymer and a fragrance, capturing a plurality of images of a surface of the dissolvable article using a three dimensional imaging device, wherein the plurality of images have different spatial properties and wherein the plurality of images are of a substantially similar viewing area of the three-dimensional imaging device, and determining a measurement of pore density and surface roughness of the surface of the dissolvable article.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: January 30, 2024
    Assignee: Henkel AG & Co. KGaA
    Inventors: Daniel Piorkowski, Joseph D. Dahlmeyer, Jr.
  • Alcoholic beverage containing steviol glycosides
    Patent number: 11884903
    Abstract: The present invention pertains to an alcoholic beverage that contains one or more types of steviol glycosides selected from rebaudioside D and rebaudioside M, and has a steviol glycoside content of 0.001-0.5 g/1,000 ml and an alcohol content of 0.5-40.0 v/v %.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: January 30, 2024
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventors: Yasuko Fujiwara, Mika Kono, Yuriko Watanabe
  • Gas fermentation using multiple-pass trickle bed reactors
    Patent number: 11884904
    Abstract: The subject matter of this application is using novel biological reactors for the fermentation of gases into liquid products. More specifically, the subject matter relates to the use of a Multiple-Pass Trickle Bed Reactor (MP-TBR) for the anaerobic or aerobic and biological fermentation of gases generated from industrial processes and/or from the gasification of biomass and other organic carbon sources. The products may include, but are not limited to, ethanol and other valuable chemicals.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: January 30, 2024
    Assignee: ICM, Inc.
    Inventors: Albert Bennett, Jonathan N. Orr
  • Fluidic chip for cell culture use, culture vessel, and culture method
    Patent number: 11884905
    Abstract: The present invention provides a fluidic chip for cell culture use which can prevent a decrease in the activity of cultured cells in a preparation stage, and which makes it possible to observe a cultured cell tissue while detaching the cultured cell tissue from the fluidic chip.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 30, 2024
    Assignee: UNIVERSITY PUBLIC CORPORATION OSAKA
    Inventor: Masaya Hagiwara
  • 4D-perfused tumoroid-on-a-chip platform for personalized cancer treatment applications
    Patent number: 11884906
    Abstract: A 4D-perfused tumoroid-on-a-chip platform used in personalized cancer treatment. The platform includes a plate with a plurality of bottomless wells that resides atop a microfluidic channel layer, which in turn resides atop a surface acoustic wave (SAW) based sensor layer that is capable of measuring potential pH values of fluids disposed within the platform. The microfluidic channel layer includes a plurality of bioreactors, with each bioreactor including an inlet well, a culture well, and an outlet well. The inlet well, culture well, and outlet well form a closed system via fluid conduits spanning from the inlet well to the culture well, as well as from the culture well to the outlet well. Due to the fluid flow from the plate to the chip, and from the inlet well to the outlet well on the chip through the culture well, target cell (tumoroid) growth is promoted within the culture well.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: January 30, 2024
    Assignee: University of South Florida
    Inventors: Subhra Mohapatra, Shyam S. Mohapatra, Tao Wang
  • Culture container, method for culturing lymphocytes, culture-container production method, and solid-phasing apparatus
    Patent number: 11884907
    Abstract: A culture container for culturing lymphocytes includes an immobilized surface and a non-immobilized surface, wherein the culture container is formed of a gas permeable film, the immobilized surface and the non-immobilized surface are container inner surfaces facing each other, and anti-CD3 antibodies are immobilized in the immobilized surface at a concentration of 10 to 300 ng/cm2.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: January 30, 2024
    Assignee: TOYO SEIKAN GROUP HOLDINGS, LTD.
    Inventors: Takahiko Totani, Satoshi Tanaka, Takeshi Aihara, Yoichi Ishizaki
  • 3D cell automated incubator
    Patent number: 11884908
    Abstract: This application relates to an automated three-dimensional (3D) cell culture system. The system includes a first body including a cell culture space in which a scaffold, on which cells are cultured, is provided and the cells are cultured thereon, and a medium storage space which is partitioned from the cell culture space by a first partition wall, in which a medium is provided and stored, and which surrounds the cell culture space, wherein the first partition wall has a drain hole to communicate the medium storage space with the cell culture space. The system also includes a communication pipe provided at the first partition wall to drain the medium of the cell culture space to the outside by a siphon action. The system further includes a second body including a medium recovery space located under the first body and recovering and externally draining the medium drained through the communication pipe.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 30, 2024
    Assignee: Danagreen Co., Ltd.
    Inventor: Seung Yon Ju
  • Cluster airlift bioreactor
    Patent number: 11884909
    Abstract: A bioreactor includes a plurality of spargers and a plurality of vertical circulation loops. A first vertical circulation loop of the plurality of vertical circulation loops includes a first sparging region and a first return region. The first vertical circulation loop is in liquid communication with one or more other loops of the plurality of vertical circulation loops. The first vertical circulation loop is characterized by an individual loop mass transfer coefficient. A controller is coupled to the plurality of spargers and configured to control the plurality of spargers together such that a cumulative mass transfer coefficient of the plurality of vertical circulation loops is within a threshold of the individual loop mass transfer coefficient associated with the first vertical circulation loop.
    Type: Grant
    Filed: March 24, 2023
    Date of Patent: January 30, 2024
    Assignee: Ark Biotech Inc.
    Inventors: Zheng Huang, Kai Hoeffner, Orianna Elysse Kane
  • Incubator with air curtain
    Patent number: 11884910
    Abstract: An incubator for cell and tissue culture under controlled atmospheric conditions has a primary air flow control device that forms a primary, preferably laminar flow, air veil across an opening that allows access to the cells or tissue cultures disposed within the incubator. Preferably, most if not all of the air in the primary (laminar flow) air veil is recirculated, and a secondary air flow control device is used that forms a secondary, preferably laminar flow, air veil between the primary (laminar flow) air veil and a user of the incubator.
    Type: Grant
    Filed: August 3, 2023
    Date of Patent: January 30, 2024
    Assignee: Embrient, Inc.
    Inventors: Kyong-su Son, Royal Q. Le, Barry E. Rothenberg
  • Cell culture device, system and methods of use thereof
    Patent number: 11884911
    Abstract: The present invention provides a method for culturing cells in a cell culture container having a base section, a top section arranged in parallel with the top section and a wall element arranged between the top section and the base section and defining an internal lumen of the container, in which the wall element of the container is compressible with respect to the top and bottom section, and in which the top section of the container has an optionally sealable inlet, in which the container is composed of a flexible material, comprising culturing cells in a culture medium in the cell culture container.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: January 30, 2024
    Assignee: Oribiotech Ltd.
    Inventors: Christopher Mason, Farlan Veraitch
  • Cell culture device and method thereof
    Patent number: 11884912
    Abstract: A cell culture device includes a culture unit, a gas supply unit, a first pressure unit, at least one inspecting unit and a control unit. The culture unit contains a cell culture liquid. The gas supply unit, connected with the culture unit, is used for transmitting a culture gas into the culture unit. The first pressure unit, connected with the culture unit, is used for applying a pressure to the cell culture liquid in the culture unit. The at least one inspecting unit, connected with the culture unit, is used for receiving the cell culture liquid for inspection. The control unit, electrically coupled with the culture unit, the first pressure unit, the gas supply unit and the at least one inspecting unit, is used for monitoring corresponding condition parameters to determine respective operations. In addition, a cell culture method for the cell culture device is also provided.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: January 30, 2024
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Kuo-Hsing Wen, Ting-Hsuan Chen, Cheng-Tai Chen, Chien-An Chen, Su-Fung Chiu, Yung-Chi Chang, Nien-Jen Chou, Ping-Jung Wu, Shaw-Hwa Parng, Pei-Shin Jiang
  • Instrument resource scheduling
    Patent number: 11884913
    Abstract: Aspects of the present invention relate to an automated cell culture instrument and to methods for operating such an instrument. In one aspect, the cell culture instrument includes a computing unit and a plurality of electrically controllable resources (e.g., sensors, actuators, etc.). The computing unit receives a protocol, schedules the resources so as to execute the protocol, and operates the resources as scheduled or in response to so as to provide an improved environment for cell culture growth. The computing unit may simulate protocol execution in connection with the scheduling or execution of the protocol.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: January 30, 2024
    Assignee: Thrive Bioscience, Inc.
    Inventors: Howard Cannon, Keith Moulton
  • sp. strains for efficient biomass production using greenhouse gases
    Patent number: 11884914
    Abstract: The invention is directed to Haematococcus sp. KAU-01 as well as to a culture medium for Haematococcus sp. KAU-01, and to methods for using this strain to process environmental pollutants such as gases generated by coal-fired plants.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: January 30, 2024
    Assignee: King Abdulaziz University
    Inventors: Adnan Jaman Turki, Md. Abu Affan, Salim Marzoog Al-Harbi
  • Guide RNAs with chemical modification for prime editing
    Patent number: 11884915
    Abstract: Provided herein are compositions and methods for inducing CRISPR/Cas-based editing of a target nucleic acid (e.g., target DNA or target RNA) in vitro or in a cell, using modified prime editing guide RNAs (pegRNAs) that incorporate one or more chemically-modified nucleotides. The modified pegRNAs disclosed herein may be used to induce Cas-mediated incorporation of one or more nucleotide changes and/or targeted mutagenesis of a target nucleic acid. The nucleotide change can include, e.g., one or more nucleotide changes, an insertion of one or more nucleotides, or a deletion of one or more nucleotides.
    Type: Grant
    Filed: September 12, 2022
    Date of Patent: January 30, 2024
    Assignee: Agilent Technologies, Inc.
    Inventors: Daniel E. Ryan, Robert Kaiser, Douglas J. Dellinger
  • Materials and methods for the synthesis of error-minimized nucleic acid molecules
    Patent number: 11884916
    Abstract: The present invention provides materials and methods useful for error correction of nucleic acid molecules. In one embodiment of the invention, a first plurality of double-stranded nucleic acid molecules having a nucleotide mismatch are fragmented by exposure to a molecule having unidirectional mismatch endonuclease activity. The nucleic acid molecules are cut at the mismatch site or near the mismatch site, leaving a double-stranded nucleic acid molecule having a mismatch at the end or near end of the molecule. The nucleic acid molecule is then exposed to a molecule having unidirectional exonuclease activity to remove the mismatched nucleotide. The missing nucleotides can then be filled in by the action of, e.g., a molecule having DNA polymerase activity. The result is double-stranded nucleic acid molecules with a decreased frequency of nucleotide mismatches.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: January 30, 2024
    Assignee: Telesis Bio Inc.
    Inventors: Daniel G Gibson, Nicky Caiazza, Toby H. Richardson
  • Conditional CRISPR sgRNA expression
    Patent number: 11884917
    Abstract: An expression cassette for conditional expression of a single guide RNA (sgRNA) of a CRISPR/Cas9 system, the cassette includes a promoter, an sgRNA sequence, and a sequence flanked by at least a pair of recombinase recognition sites, wherein recombinase activated re-combination at the pair of recombinase recognition sites is capable of excising said flanked sequence, whereby either i) at least one of said recombinase recognition sites is located within the sgRNA sequence and said flanked sequence contains an transcription disruption sequence or ii) said flanked sequence is at least a part of the promoter or of the sgRNA sequence; methods of conditional expression of sgRNA and a reaction product of the conditional expression, i.e. sgRNA with a recombination site remnant.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: January 30, 2024
    Assignees: IMBA—INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH, CAMPUS SCIENCE SUPPORT FACILITIES GMBH
    Inventors: Ulrich Elling, Krzysztof Chylinski, Maria Hubmann, Monika Borowska, Ivana Bilusic-Vilagos
  • Systems and methods for modulating CRISPR activity
    Patent number: 11884918
    Abstract: Provided herein are polynucleotides comprising sequence configured to bind to a CRISPR effector protein. Modulation of one or more modifications of the polynucleotides can be used to tune the activity of CRISPR effector proteins complexed with the polynucleotides.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: January 30, 2024
    Assignee: Synthego Corporation
    Inventors: Reed Kelso, Jared Carlson-Stevermer, Sahil Joshi, Travis Maures, Anastasia Kadina, John Andrew Walker, II
  • Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
    Patent number: 11884919
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: January 30, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
    Patent number: 11884920
    Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: January 30, 2024
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
  • Signal boost cascade assay
    Patent number: 11884921
    Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods provide signal boost upon detection of target nucleic acids of interest in less than one minute and in some instances instantaneously at ambient temperatures down to 16° C. or less, without amplification of the target nucleic acids yet allowing for massive multiplexing, high accuracy and minimal non-specific signal generation.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: January 30, 2024
    Assignee: VedaBio, Inc.
    Inventors: Anurup Ganguli, Ashish Pandey, Ariana Mostafa, Jacob Berger
  • Tuning cascade assay kinetics via molecular design
    Patent number: 11884922
    Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods allow one to control reaction kinetics of the cascade assay by two orders of magnitude via molecular design of one of the reaction components; further, varying molecular design also allows for quantification of target nucleic acids of interest over a large range of concentrations or discriminating between extremely low copy numbers of target nucleic acids of interest.
    Type: Grant
    Filed: June 10, 2023
    Date of Patent: January 30, 2024
    Assignee: VedaBio, Inc.
    Inventors: Ariana Mostafa, Jacob Berger, Ashish Pandey, Anurup Ganguli
  • Fructose-4-epimerase and method of producing tagatose using the same
    Patent number: 11884923
    Abstract: Provided are a fructose-4-epimerase variant having tagatose conversion activity, and a method of preparing tagatose using the same.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: January 30, 2024
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Young Mi Lee, Eul-Soo Park, Il Hyang Park, Sun Mi Shin, Sung Jae Yang, Ran Young Yoon, Eun Jung Choi, Seong Bo Kim, Seung Won Park
  • Dual strand nucleic acid-guided nickase editing
    Patent number: 11884924
    Abstract: The present disclosure provides compositions of matter, methods and instruments for nucleic acid-guided nickase/reverse transcriptase fusion enzyme editing of nucleic acids in live mammalian cells.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: January 30, 2024
    Assignee: Inscripta, Inc.
    Inventors: Brian Chaikind, Aamir Mir
  • Synthetic immunomodulation with a CRISPR super-repressor in vivo
    Patent number: 11884925
    Abstract: Provided herein are CRISPR-based synthetic repression systems as well as methods and compositions using the synthetic repression systems to treat septicemia, an adverse immune response in a subject and Waldenström macroglobulinemia.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: January 30, 2024
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Samira Kiani, Mo Reza Ebrahimkhani, Farzaneh Moghadam
  • Campaign-ready series of recombinant adeno-associated virus (rAAV) complementing plasmids
    Patent number: 11884926
    Abstract: In some aspects, the disclosure relates to compositions and methods for production of recombinant adeno-associated virus (rAAV) particles. The disclosure is based, in part, on isolated nucleic acids and systems that include only two vectors and are suitable for production of multiple different single gene viral vectors in a multiple small-scale campaign mode (e.g., 1013 to 1016 viral particles.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: January 30, 2024
    Assignee: University of Massachusetts
    Inventors: Terence Flotte, Qiushi Tang, Allison Keeler-Klunk, Qin Su
  • Fusion constructs as protein over-expression vectors
    Patent number: 11884927
    Abstract: This invention provides compositions and methods for providing high product yield of transgenes expressed in cyanobacteria and microalgae.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: January 30, 2024
    Assignee: The Regents of the University of California
    Inventors: Anastasios Melis, Cinzia Formighieri
  • Methods for genetic engineering host cells
    Patent number: 11884928
    Abstract: The invention provides methods for genetically engineering Kluyveromyces. The methods can be used to genetically engineer Kluyveromyces to produce and secrete full-length antibodies or antibody fragments. The invention also provides methods for production and secretion of antibodies.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: January 30, 2024
    Assignee: Amyris, Inc.
    Inventor: Yoseph Tsegaye
  • CPMV enhancer elements
    Patent number: 11884929
    Abstract: An expression enhancer comprising a CPMV 5?UTR nucleotide sequence consisting of X nucleotides (CMPVX), where X=160, 155, 150, or 114 of SEQ ID NO:1, or consisting of a nucleotide sequence comprising from about 80% to 100% sequence similarity with CMPVX, where X=160, 155, 150, or 114 of SEQ ID NO:1 SEQ ID NO:1 is provided. The expression enhancer may further comprise a stuffer sequence fused to the 3? end of the 5?UTR nucleotide sequence (CMPVX+, where X=160, 155, 150, or 114 of SEQ ID NO:1). The stuffer sequence may comprise one or more plant kozak sequences.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: January 30, 2024
    Assignee: Medicago Inc.
    Inventors: Pierre-Olivier Lavoie, Marc-Andre D'Aoust
  • Method of inactivating a glucocorticoid receptor gene in an isolated cell
    Patent number: 11884930
    Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: January 30, 2024
    Assignees: Sangamo Biosciences, Inc., City of Hope
    Inventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
  • Oncolytic virus for colorectal cancer treatment using colorectal cancer cell-specific infectious newcastle disease virus and composition for colorectal cancer treatment using same
    Patent number: 11884931
    Abstract: Provided is an M2-LVP-K1 virus including a colorectal cancer cell-specific mutant sialic acid binding domain and a composition for treating colorectal cancer including the same. The mutant sialic acid binding domain is constructed using directed evolution technology, and is a recombinant Newcastle disease virus constructed by substituting a normal sialic acid binding domain for a HN protein, a cell-binding receptor, to improve the specific infectivity to HCT116 cells. It was identified that M2-LVP-K1 recombinant Newcastle disease virus with improved colorectal cancer cell-specific infectivity has improved HCT116 cell death effect compared to the conventional normal recombinant Newcastle disease virus, and produces an excellent effect in inhibiting cancer tissue growth through in vivo experiments.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: January 30, 2024
    Assignee: LIBENTECH CO., LTD.
    Inventors: Hyun Jang, Bo Kyoung Jung, Yong Hee An
  • In vitro production of medial ganglionic eminence precursor cells
    Patent number: 11884932
    Abstract: Methods and systems for generating MGE precursor cells in vitro as well as compositions of enriched MGE precursor cells are provided. The methods and systems provide efficient production of MGE precursors. The methods and systems disclosed herein provide functional MGE precursors which differentiate into functional GABAergic interneurons.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: January 30, 2024
    Assignee: The Regents of the University of California
    Inventors: Cory R. Nicholas, John L. Rubenstein, Arnold R. Kriegstein, Arturo Alvarez-Buylla
  • Supported in vitro developed tissue culture and culturing methods
    Patent number: 11884933
    Abstract: An elongated or fiber-supported multicellular aggregation of multipotent cells, wherein multipotent cells are arranged in an oblong or longish arrangement with an aspect ratio of a prolate dimension to a perpendicular dimension of at least 2:1, or supported by a fibrous structure, and wherein the aggregate contains cells at different stages of differentiation, and the aggregate contains polar cells; methods of generating such aggregates; methods of developing the aggregates further into tissue organoids and kits for such methods.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: January 30, 2024
    Assignee: IMBA—INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Jürgen Knoblich, Madeline A. Lancaster
  • Methods and compositions for T cell activation
    Patent number: 11884934
    Abstract: Among the various aspects of the present disclosure is the provision of methods, synthetic DC, and compositions for T cell activation. The present disclosure provides for synthetic dendritic cells (DCs), methods of generating synthetic dendritic cells (DCs), methods of generating T cell-encapsulated gelatin microspheres and microcapsules, methods of activating T cells using synthetic DCs, methods for expanding T cells against individualized antigen-specific mutational antigens using synthetic DCs, and methods of treating a chronic disease (e.g., HIV, HPV) or cancer using the synthetic DCs.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: January 30, 2024
    Assignee: Washington University
    Inventors: Eynav Klechevsky, Amit Pathak, Bapi Sarker
  • Method for inducing trans-differentiation of cardiomyocytes based on exosome
    Patent number: 11884935
    Abstract: The present invention relates to a method for inducing trans-differentiation of cardiomyocytes based on exosome, and more particularly, to a method for inducing trans-differentiation of a fibroblast into a cardiomyocyte, comprising the steps of: isolating exosomes in a culture medium during a process of differentiating a stem cell into the cardiomyocyte; culturing a fibroblast in a cardiomyocyte reprogramming medium containing the isolated exosomes; and culturing the fibroblast cultured in a cardiomyocyte differentiation medium containing the isolated exosomes.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 30, 2024
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ick Chan Kwon, Sun Hwa Kim, Yoosoo Yang, Hyosuk Kim
  • Stromal stem cells
    Patent number: 11884936
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: January 30, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mRNA
    Patent number: 11884937
    Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: January 30, 2024
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Eduard Yakubov
  • Cell culture system
    Patent number: 11884938
    Abstract: The embodiments of the invention described herein relate to systems and methods for culturing and/or maintaining intestinal cells, tissues and/or organoids in vitro. The cells, tissues and/or organoids cultured according to the methods and systems described herein can mimic or reproduce natural intestinal epithelial structures and behavior as well as support co-culture of intestinal microflora.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: January 30, 2024
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Donald E. Ingber, Hyun Jung Kim
  • Vaccinia virus mutants useful for cancer immunotherapy
    Patent number: 11884939
    Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVA?C7L and VACV?C7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVA?C7L or VACV?C7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: January 30, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Ning Yang, Taha Merghoub, Jedd Wolchok
  • Multi-substrate metabolism for improving biomass and lipid production
    Patent number: 11884940
    Abstract: The present application relates to methods to improve biomass or lipid production in a microorganism from one or more fatty acid and one or more simple carbon co-substrates. Produced lipids may include unsaturated C6-C24 fatty acids, alcohols, aldehydes, and acetates which may be useful as final products or precursors to insect pheromones, fragrances, flavors, and polymer intermediates. The application further relates to recombinant microorganisms modified for improved production of biomass or lipid, or improved lipid selectivity. Also provided are methods of producing one or more lipid using the recombinant microorganisms, as well as compositions comprising the recombinant microorganisms and/or optionally one or more of the product lipid.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: January 30, 2024
    Assignee: Provivi, Inc.
    Inventors: Effendi Leonard, Micah Sheppard, Thomas Heel, Kathryn Christina Wu
  • Non-canonical lipoproteins with programmable assembly and architecture and method of making non-canonical lipoproteins
    Patent number: 11884941
    Abstract: Artificial lipoproteins bearing non-canonical post-translational modifications that are synthesized by leveraging substrate promiscuity of an acyltransferase. The non-canonical functionality of these lipoprotein results in a distinctive hysteretic assembly that is absent from the canonical lipoproteins and is used to prepare hybrid multiblock materials with precise and programmable patterns of amphiphilicity due to the unique assembly and function of the non-canonical post-translational modifications.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: January 30, 2024
    Assignee: SYRACUSE UNIVERSITY
    Inventor: Davoud Mozhdehi
  • Compositions and methods comprising the use of and ?-glucanotransferase enzymes
    Patent number: 11884942
    Abstract: An isolated and/or purified ?-glucanotransferase from Exiguobacterium acetylicum, recombinantly engineered variants thereof, active fragments thereof, synthetic nucleic acids encoding the ?-glucanotransferase and variants thereof, host cells comprising the synthetic nucleic acids, and compositions comprising the ?-glucanotransferase are provided. Methods of using the compositions include the manufacture of oligosaccharides.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: January 30, 2024
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventor: Slavko Kralj
  • Engineered enzymes and uses thereof
    Patent number: 11884943
    Abstract: Provided herein are modified Archaeal family B polymerases derived from species of the Archaeal microorganism Pyrococcus that exhibit improved incorporation of nucleotide analogues utilized in DNA sequencing.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: January 30, 2024
    Assignee: Singular Genomics Systems, Inc.
    Inventors: Souad Naji, Eli N. Glezer, Youngjin Cho, Zachary Terranova, Abrehet Abdu
  • Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
    Patent number: 11884944
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: January 30, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Tina Giese, Gunasekaran Kannan, Mihalis S. Kariolis, Cathal S. Mahon
  • Methods for purification of arylsulfatase A
    Patent number: 11884945
    Abstract: The present invention provides, among other things, improved methods for purifying arylsulfatase A (ASA) protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant ASA protein can be purified from unprocessed biological materials, such as, ASA-containing cell culture medium, using a process involving as few as four chromatography columns and only one step of post-chromatographic ultrafiltration/diafiltration.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: January 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Dave Nichols, Igor Quinones-Garcia, Bee Lin Cheang, Mei Huei Jang
  • Generation of stable protein films using fluorous solvent
    Patent number: 11884946
    Abstract: Methods of preparing protein films in the presence of organofluorine compounds are provided that can produce protein films that retain the solution phase characteristics of the proteins. The protein films can be coatings for medical devices.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: January 30, 2024
    Assignee: University of Massachusetts
    Inventors: Li-Sheng Wang, Sanjana Gopalakrishnan, Vincent M. Rotello
  • Fusion proteins for base editing
    Patent number: 11884947
    Abstract: Provided are fusion proteins that include an apolipoprotein B mRNA editing enzyme catalytic subunit 3A (APOBEC3A) and a clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein, optionally further with uracil glycosylase inhibitor (UGI). Such a fusion protein is able to conduct base editing in DNA by deaminating cytosine to uracil, even when the cytosine is in a GpC context or is methylated.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: January 30, 2024
    Assignee: ShanghaiTech University
    Inventors: Jia Chen, Li Yang, Xingxu Huang, Bei Yang, Xiao Wang, Jianan Li
  • Genetically modified organisms for production of polyketides
    Patent number: 11884948
    Abstract: Strains of yeasts are provided containing the genes for the production of cannabinoids from fatty acids. The enzymes that mediate cannabinoid production are localized to the cytosol, peroxisome or different compartments within the secretory pathway (e.g., endoplasmic reticulum, Golgi, vacuole) to ensure efficient production. The engineered microorganisms produce cannabinoids in a controlled fermentation process.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: January 30, 2024
    Assignee: PYRONE SYSTEMS, INC.
    Inventors: Alexander Hutagalung, Jose Miguel Laplaza
  • Methods of producing morphinan alkaloids and derivatives
    Patent number: 11884949
    Abstract: A method of producing promorphinan, morphinan, nal-opioid, and nor-opioid alkaloid products through the increased conversion of a promorphinan alkaloid to a morphinan alkaloid. The method comprises contacting the promorphinan alkaloid with at least one enzyme. Contacting the promorphinan alkaloid with the at least one enzyme converts the promorphinan alkaloid to a morphinan alkaloid.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: January 30, 2024
    Assignee: Antheia, Inc.
    Inventors: Christina D. Smolke, Isis Trenchard, Kristy M. Hawkins, Catherine Thodey
  • Methods and reagents for synthesising polynucleotide molecules
    Patent number: 11884950
    Abstract: The invention relates to new methods for synthesising polynucleotide molecules according to a predefined nucleotide sequence. The invention also relates to methods for the assembly of synthetic polynucleotides following synthesis, as well as systems and kits for performing the synthesis and/or assembly methods.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: January 30, 2024
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: John Milton, Sobia Nayyar, Jan Riedl, Ryosuke Ogaki
  • Method for producing RNA
    Patent number: 11884951
    Abstract: A method for producing RNA is provided. Objective RNA is produced by culturing a coryneform bacterium having an expression unit for the objective RNA, which has been modified so that the activity of ribonuclease III is reduced, in a medium, to express the objective RNA and accumulate the objective RNA in cells of the bacterium, and collecting the objective RNA from the cells.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: January 30, 2024
    Assignee: AJINOMOTO CO., INC.
    Inventors: Shuhei Hashiro, Hisashi Yasueda, Mayu Mitsuhashi, Sergei Vladimirovich Mashko, Aleksandr Aleksandrovich Krylov, Yuliya Sergeevna Lobanova